Pharmaceuticals
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites
MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injectio...
2023-05-08 05:00
2236
Empowering Innovation to the Global Market with Acro Certify
TOKYO, May 6, 2023 /PRNewswire/ -- For many companies, entering the global market is a daunting challenge. It is an immense logistical and financial challenge that makes or breaks a company, despite the product itself. For companies in that awkward, transitional stage from start-up company to a m...
2023-05-06 10:18
4295
Viva Biotech's Recent Conferences & Events Review
HONG KONG, May 5, 2023 /PRNewswire/ -- In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Research (AACR) Annual Meeting 2023, CPHI Japan 2023, PharmFuture 2023 Small Molecule Innovative Drug Fu...
2023-05-05 19:58
3752
P&G Health commemorates Neuropathy Awareness Week 2023 with an effort to help people 'Put Life Back in Their Hands'
* Dons the purple ribbon for the 2nd consecutive year to raise awareness on Peripheral Neuropathy, a condition significantly underdiagnosed and undertreated inAsia, Middle East & Africa * Releases new research study highlighting the role of B Vitamins in supporting healthy nerve functions SIN...
2023-05-05 11:30
3433
SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology
* SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistantE. coli, which can cause fatal infections in vulnerable hematological cancer patients * SNIPR001 represents the first CRISPR- therapeutic developed to specifically removeE. coli in the ...
2023-05-05 00:52
2571
ANGUS ANNOUNCES CORPORATE REBRANDING, WILL CHANGE NAME TO "ADVANCION"
New name and brand reflect Company's strategic transformation into a leading global producer of specialty ingredients for Life Sciences, Personal Care and other essential markets BUFFALO GROVE, Ill., May 4, 2023 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company") today unveiled a new n...
2023-05-04 21:00
3329
First Subject Enrolled in Boan Biotech's International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102
YANTAI, China, May 4, 2023 /PRNewswire/ -- Boan Biotech today announced that an international multi-center Phase 3 clinical study for its in-house developed Denosumab Injection (BA6101; BA1102) has been initiated inEurope, the United States, and Japan, and recently the first patient in (FPI) was ...
2023-05-04 14:40
3663
SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector
ZUG, Switerland, May 3, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for infl...
2023-05-03 22:43
2528
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)". The Harmonic™ s...
2023-05-03 21:00
2032
Chula Researchers Develop Rapid MTB Strip Test for Tuberculosis
Lecturers of the Faculty of Allied Health Sciences, Chulalongkorn University have developed the MTB Strip Test Kit for Tuberculosis (TB) diagnosis that's accurate and easy to use, guaranteed by the 2023 Invention Award from the National Research Council of Thailand (NRCT) -- Another hope to reduce...
2023-05-03 11:34
3022
Merck Signs MoU with Ministry of Trade, Industry & Energy and Daejeon City for New Asia Pacific BioProcessing Production Center in South Korea
* MoU with Merck's Life Science business aimed at supporting the region's healthcare ecosystem * Proposed bioprocessing facility to be based in Daejeon City * Further collaboration aims to support emerging biotech companies and academic research DAEJEON CITY, South Korea, May 3, 2023 /PRNe...
2023-05-03 10:00
3110
Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients
SUZHOU, China, May 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that the enrollment of ...
2023-05-03 08:00
3573
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment S...
2023-05-03 00:22
3148
Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis
* First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS). * Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803. HOUSTON, May 3, 2023 /PRNewswire/ -- Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic...
2023-05-03 00:07
1903
Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne
HANGZHOU and SHAOXING, China, May 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ASC40 (Denifanstat), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor, achieved primary and key secondary endpoints in Phase II clinical trial for acn...
2023-05-02 17:30
2817
First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide
MELBOURNE, Australia, May 2, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged inCanada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for i...
2023-05-02 05:00
2120
Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease
TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an
Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel
MagicTouch
2023-05-01 18:30
2563
ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89 Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalT...
2023-05-01 08:58
2493
Brii Bio Publishes 2022 Environmental, Social and Governance Report
Brii Bio receives an "A" grade in the latest MSCI ESG Rating
DURHAM, N.C. and BEIJING, April 28, 2023 /PRNewswire/ -- Brii Biosciences
Limited
2023-04-28 09:00
2642
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine
GERMANTOWN, Md. and GUANGZHOU, China, April 28, 2023 /PRNewswire/ -- RNAimmune, Inc.(the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the Uni...
2023-04-28 00:29
2786
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
8263
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
6458
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
6406
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
6176
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
6139
